Robert Hershberg Sells 30,664 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Director Robert Hershberg sold 30,664 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $24.40, for a total transaction of $748,201.60. Following the completion of the sale, the director owned 46,683 shares of the company’s stock, valued at $1,139,065.20. This trade represents a 39.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Adaptive Biotechnologies Stock Performance

Adaptive Biotechnologies stock opened at $25.99 on Friday. Adaptive Biotechnologies Corporation has a fifty-two week low of $12.00 and a fifty-two week high of $26.16. The stock’s 50 day simple moving average is $22.06 and its two-hundred day simple moving average is $17.35. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. The stock has a market cap of $4.15 billion, a price-to-earnings ratio of -63.39 and a beta of 2.08.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The firm had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm’s revenue was up 21.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.17) EPS. As a group, analysts expect that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ADPT shares. Piper Sandler raised their price objective on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. TD Cowen lifted their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $24.42.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd bought a new position in shares of Adaptive Biotechnologies during the fourth quarter valued at $28,000. Nykredit A S bought a new position in Adaptive Biotechnologies in the 2nd quarter worth about $31,000. Allworth Financial LP purchased a new stake in Adaptive Biotechnologies during the 2nd quarter valued at about $35,000. EverSource Wealth Advisors LLC grew its position in Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares during the last quarter. Finally, KBC Group NV bought a new stake in Adaptive Biotechnologies during the 1st quarter valued at about $45,000. 99.17% of the stock is owned by institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.